CW stock rose approximately +12% over the last 30 days, driven by strong defense sector momentum and analyst price target increases. Over the past quarter, shares gained +15%, supported by robust Q4 2025 earnings beat, record backlog, and positive 2026 guidance.
PWR stock rose approximately +5% over the last 30 days amid volatile trading, driven by strong backlog growth and positive analyst sentiment. Over the past quarter, shares gained around +30%, fueled by robust Q4 2025 earnings beat and demand for infrastructure solutions.
NOC stock declined approximately -8% over the past 30 days amid profit-taking after a strong quarterly rally and mixed sector sentiment. Over the past quarter, shares rose +8%, driven by robust Q4 2025 earnings beat, record backlog, and defense contract wins.
Rio Tinto's half-year results for the six months ended June 30, 2026, are scheduled for release on July 29, 2026. Analysts expect continued strength in copper production from Oyu Tolgoi ramp-up, offsetting potential iron ore price volatility.
RIO stock rose +12% over the last 30 days, driven by strong copper production beats and interest in U. S.
VZ stock declined approximately -10% over the past 30 days amid analyst downgrades, profit-taking after a strong quarterly rally, and sector-wide pressures in telecommunications. Over the past quarter, the stock surged +23%, driven by robust Q4 2025 earnings beat, upbeat 2026 guidance, and strong subscriber growth including over 1 million net adds.
SYRE shares surged approximately 25% in Monday's session, with the stock rising from a previous close of $51.29 to approximately $64.11 intraday. The primary catalyst is a highly positive Phase 2 SKYLINE trial readout: SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001) at Week 12 in moderate-to-severely active ulcerative colitis patients.
Shares of Revolution Medicines (RVMD) surged +37.33% in today's session, rising from a prior close of $96.43 to $132.43, with an intraday high of $135.81. The primary catalyst is a landmark Phase 3 clinical trial win: daraxonrasib nearly doubled median overall survival versus standard chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC)
LITE shares are trading down approximately 5% in Monday's session (April 13, 2026), from a prior close of $897.30 to roughly $852.44. The decline is driven primarily by broad market risk-off sentiment tied to geopolitical tensions and ongoing tariff uncertainty, with no company-specific negative catalyst.
ERAS shares declined approximately -12% intraday on Monday, April 13, 2026, pulling back sharply from a recent 52-week high of $18.20 reached on April 7. The selloff appears primarily driven by profit-taking and valuation pressure after a staggering ~1,497% rally over the past twelve months, with shares trading well above most pre-run analyst consensus targets.
Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75. The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
Analysts expect Q1 2026 EPS of approximately $4.77-$4.85, up slightly from $4.65 in Q1 2025. Revenue consensus around $22.6B-$23.2B, reflecting 9.7%-4.5% year-over-year growth.
Morgan Stanley (MS) stock surged +15% over the past 30 days, driven by the launch of its low-cost Bitcoin ETF and positive analyst upgrades ahead of Q1 earnings. Over the past quarter, the stock is relatively flat at -1%, reflecting volatility from geopolitical tensions and private credit concerns offset by a strong rebound.
Goldman Sachs ( GS ) reports Q1 2026 earnings on April 13, with consensus EPS of $16.34 and revenue of $16.95 billion, signaling 16% EPS growth year-over-year. Morgan Stanley ( MS ) follows on April 15, expecting EPS of $3.02 and revenue of $19.71 billion, up 16% in EPS.
BAC stock rose approximately +11% over the past 30 days, rebounding from mid-March lows around $47 amid positive net interest income (NII, the difference between interest earned on loans and paid on deposits) guidance and analyst upgrades. Over the past quarter, the stock declined about -5%, reflecting earlier pressures from peak levels near $55 in January due to interest rate volatility and macroeconomic concerns.
ASML stock rose +9.9% over the past 30 days amid AI-driven demand for extreme ultraviolet (EUV) lithography systems, despite volatility from proposed U.S. export restrictions to China. Over the past quarter, shares gained +16.4%, supported by record bookings and strong semiconductor industry capex (capital expenditures) trends.
First Horizon ( FHN ) reports Q1 2026 earnings on April 15, with consensus EPS of $0.49 and revenue of $869 million. F.
INTU stock declined approximately -18% over the past 30 days, driven primarily by sector-wide fears of AI disruption following Anthropic's new model announcements. Over the past quarter, the stock fell around -46%, reflecting broader software sector weakness amid macroeconomic uncertainty and valuation resets.
SMH rose +10.6% over the past 30 days, driven by AI chip demand recovery and easing geopolitical tensions from Iran war ceasefire hopes. Quarterly performance shows +13.0% gain, supported by strong earnings from top holdings like NVIDIA and Taiwan Semiconductor amid sustained AI infrastructure buildout.
Salesforce (CRM) stock declined approximately -12% over the past 30 days amid sector-wide selloffs in software stocks driven by AI disruption fears. Over the past quarter, the stock fell around -35%, reflecting broader YTD losses of over 35% from early-year highs near $260.